Stifel 2026 Healthcare Conference - EXELIXIS INC

Financial Performance:

• The transcript contains no specific disclosed figures for current revenue, earnings, profit margins, or cash flow, focusing instead on strategic capital allocation rather than financial reporting.
• Management highlights a strategy of cost efficiency by partnering with clinical collaborators to fund 50% of pivotal studies, effectively doubling the trial portfolio size without increasing capital expenditure.
• The company maintains a disciplined approach to capital stewardship, prioritizing the avoidance of "value destruction" from unfavorable M&A or BD activities.

Guidance and Future Outlook:

• Zanzalit Nib (Zanza) PDUFA: The Phase 3 Stellar 304 trial in non-clear cell renal cancer (RCC) is expected to yield top-line data in Q1 of next year, delayed from year-end due to slower-than-anticipated event accrual rates.
• Colorectal Cancer (CRC): Seeking FDA approval for the Zanza + Tezzo combination in third-line+ patients; a PDUFA extension was granted to address agency data requests, with strong confidence in a broad label covering both liver metastatic and non-liver metastatic subgroups.
• Pipeline Expansion: Anticipates launching a "second wave" of Zanza trials, including upfront metastatic RCC (following LightSpark 12 learnings) and MRD-guided treatment in the adjuvant setting (Stellar 316).
• Long-term Growth: Projects the Zanza franchise has the potential to replace and exceed the Cabo franchise, targeting a cumulative $5 billion+ opportunity across seven pivotal studies, with plans to double this set through well-designed collaborations.
• Third Franchise: Expresses a high strategic priority to acquire or develop a third product franchise by 2031 to smooth the transition post-Cabo loss of exclusivity (LOE), with a rigorous filter on commercial viability.

Business Segments and Product Lines:

• Renal Cell Carcinoma (RCC): Currently transitioning from a single-product (Cabo) to a multi-franchise company with Cabo and Zanza. Zanza is being positioned to define a new standard of care in non-clear cell RCC via Level 1 evidence from the randomized Phase 3 Stellar 304.
• Colorectal Cancer (CRC): Developing a franchise centered on Zanza + Tezzo, aiming to capture share from sunlight regimens, TKIs, and chemotherapy across a $1.5 billion market.
• Dose Optimization: Zanza dose is being optimized based on indication and line of therapy; a 60mg dose is being utilized in later-stage CRC trials (e.g., LightSpark 34) to balance efficacy and tolerability in earlier-line settings, contrasting with the 100mg dose used in late-line CRC (Stellar 303).
• New Indications: Exploring Zanza + Pembrolizumab (PEM) in the MRD-positive adjuvant colorectal setting (Stellar 316) and potential combinations in lung cancer maintenance.

Market and Competitive Landscape:

• RCC: Addresses a gap where current labels often include or exclude non-clear cell RCC arbitrarily; Zanza aims to establish a distinct standard of care with randomized data.
• Competitive Dynamics: Notes that in the second-line RCC setting, sequencing therapies (e.g., Cabo then Belzutifan) may offer comparable or superior PFS to combination therapies like LightSpark 11's candidate, with better tolerability.
• CRC Market: Characterized by a fragmented community-based prescriber model; Zanza + Tezzo aims to be chemo-free, checkpoint-containing, and active across all subgroups, including those with prior Avastin exposure.
• Market Share Goal: Target to take share equally from sunlight, TKI, and chemotherapy segments rather than competing against a single competitor.

Risks and Challenges:

• Event Accrual: Phase 3 trials face risks of slower event rates, leading to data delays (as seen with Stellar 304).
• Regulatory Uncertainty: Label breadth for CRC may depend on FDA interpretation, though data suggests broad activity across subgroups.
• Compliance and Tolerability: Historical challenges with oral TKI maintenance compliance and tolerability (e.g., SUTENT adjuvant failure) remain a risk for maintenance trials like Stellar 316; addressed via Zanza's shorter half-life allowing for titratability and dose holds.
• Pipeline Prioritization: Risk of "cutting bait" on programs that do not show differentiated potential in large markets, requiring ruthless decision-making.

Management Commentary and Tone:

• Tone: Highly confident, disciplined, and execution-focused; management explicitly contrasts their operational style ("running like a business, not a biotech") with typical biotech approaches.
• Confidence: Expresses strong conviction in the Zanza franchise's ability to scale beyond Cabo, citing robust data and strategic study designs.
• Strategic Discipline: Emphasizes that commercial viability is as critical as biology, with a "thick filter" applied to all M&A and BD opportunities to ensure long-term value creation.

Analyst Questions and Answers:

• Q&A on Stellar 304 Delay: Management clarified the delay to Q1 next year is due to slower event accumulation, with no change to the expected data robustness.
• Q&A on Zanza Dosing: Discussed the 60mg dose in LightSpark 34 as an optimization for tolerability in specific settings, confirmed via exposure-response data; not a single universal dose for all indications.
• Q&A on CRC Labeling: Addressed concerns about liver metastasis restrictions; management stated trial data shows broad activity across all subgroups, similar to PARP inhibitor patterns, suggesting a potential broad label.
• Q&A on Cabo Sustainability: Discussed the "combining vs. sequencing" debate, noting that sequencing may currently outperform combinations in second-line RCC, reinforcing the focus on front-line share for Cabo and Zanza.
• Q&A on Third Franchise: Reiterated the strategic necessity of a third product by 2031 to maintain growth, with flexibility for internal or external acquisition, provided it meets commercial rigor.

Other Key Points:

• MRD-Guided Therapy: Stellar 316 represents a first-in-class approach to MRD-guided treatment intensification in adjuvant colorectal cancer, targeting the high-risk MRD-positive population (approx. 20%) with a novel intervention beyond chemotherapy.
• Zanza's Mechanism: Highlights the synergy of Zanza's multi-kinase inhibition (VEGF, MET, AXL, MER) with immune checkpoint inhibitors, particularly in the context of the tumor microenvironment.
• Commercial Execution: Management views the commercial execution of the next franchise as the primary determinant of the revenue trajectory post-Cabo, emphasizing the need to "define and generate a data set that leaves the opportunity to be a new standard of care."